Anatomic results maintained at end of brolucizumab studies

CHICAGO — Brolucizumab maintained non-inferiority to aflibercept regarding best corrected visual acuity change at week 96, which was the end of the HAWK and HARRIER trials, according to a speaker.
In both trials, the primary endpoint of non-inferiority to aflibercept 2 mg (Regeneron) was reached at week 48.
“This was achieved whilst over 75% of brolucizumab 6 mg patients (Novartis) who completed week 48 on a q12 week interval remained on that same q12 week interval until week 96,” Pravin U. Dugel, MD, reported at Retina Subspecialty Day preceding the (Read more...)

Full Story →